Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




CT Perfusion Effective for Monitoring Treatment Response to Hepatocellular Carcinoma

By HospiMedica International staff writers
Posted on 24 Nov 2008
A new study was initiated to prospectively evaluate the changes in parameters of computed tomography (CT) perfusion imaging pre- and post-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in different treatment response groups, and to correlate the changes with various responses of HCC to TACE.

TACE has been widely accepted as a choice of treatment for advanced HCC. More...
CT perfusion is a noninvasive and reproducible technique for assessing perfusion changes due to TACE therapy for locally advanced HCC. However, there are few reports on the application of this technique in evaluating the efficacy of TACE based on quantitative analysis of perfusion parameters.

In the study published on October 7, 2008, in the World Journal of Gastroenterology, researchers led by a professor from Beijing Friendship Hospital affiliated to Capital Medical University (Beijing, China) used 64-rows multi-detector CT, which can offer a greater coverage (up to 4 cm) of the tumor and portal vein in the scanning range. A CT perfusion scan for patients with HCC allows assessment of perfusion changes due to TACE therapy. This study additionally investigated the correlation between changes in CT perfusion parameters pre- and post-TACE treatment of HCC and various responses to TACE.

The following response evaluation criteria [complete response (CR): disappearance of all target lesions; partial response (PR): at least a 30% decrease in the sum of the longest diameters (LD) of target lesions; progressive disease (PD): at least a 20% increase in the sum of the LD of target lesions; stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD] for solid tumors (RECIST) were referred to when it was necessary to assess the therapeutic effect after TACE.

In the PR treatment response group, hepatic artery perfusion (HAP), hepatic arterial fracture (HAF) and hepatic blood volume (HBV) of viable tumors were reduced post-TACE compared with before pre-TACE, while no significant difference was observed in HBF, MTT, PS, and portal vein perfusion (PVP) pre- and post-TACE. In the SD treatment response group, there was no significant difference in perfusion parameters pre- and post-TACE. In the PD treatment group, HAP, HAF, PVP, and hepatic blood flow (HBF) of viable tumors were significantly increased after TACE compared with pre-TACE, while no significant difference was found in other perfusion parameters pre- and post-TACE.

The study's findings, according to the researchers, suggested that changes in CT perfusion parameters in viable tumors are correlated with different response of HCC to TACE. Therefore, CT perfusion imaging is a viable technique for monitoring response of HCC to TACE.

Related Links:
Capital Medical University



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Digital Radiography System (Ceiling Free)
Digix CF Series
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.